Sign inJoin waitlistJoin the waitlist

Alison Conlin

, Associate Member · Providence Health & Services - Oregon

Credentials: · · · · ·

History

Providence Health & Services - Oregon
Present

New York-Presbyterian University Hospital of Columbia and Cornell
2007–2010
Memorial Sloan Kettering Cancer Center
2005–2007
New York-Presbyterian University Hospital of Columbia and Cornell
2002–2005
State University of New York Upstate Medical University
1998–2002

Research

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
New England Journal of Medicine · 2019 · 2,052 citations
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Journal of Clinical Oncology · 2020 · 452 citations
Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study
Journal of Clinical Oncology · 2017 · 323 citations

Supriya Mohile
11 papers
AS
Andrew Seidman
8 papers
Kah Loh
8 papers · 4 as a fellow
Allison Magnuson
7 papers
EM
Eleftherios Mamounas
6 papers
Colin McHugh
5 papers · 3 as a fellow
Norman Wolmark
5 papers
Paul Duberstein
5 papers
AB
Adam Brufsky
4 papers
Charles Geyer
4 papers
CH
Clifford Hudis
4 papers
David Page
4 papers

Grants

The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site
National Cancer Institute · UG1
PI · $24.4M · Swedish Medical Center, First Hill
2014–2027
Western Oncology Research Consortium
National Cancer Institute · U10
Contact PI · $2.3M · Providence Portland Medical Center
1987–2014

Clinical trials

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
Principal investigator · Withdrawn · Phase 1, Phase 2
Providence Health & Services
2021–2023
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
Principal investigator · Completed · Phase 1
Providence Health & Services
2012–2018
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2040
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029